Fate Therapeutics
Fate Therapeutics is a biopharmaceutical company dedicated to developing programmed cellular immunotherapies for cancer and autoimmune diseases. They focus on innovative cell-based therapies using their unique ex vivo cell programming approach, aiming to modulate the therapeutic function and fate of hematopoietic cells. Their mission is to transform the lives of patients with severe, life-threatening diseases by pioneering ground-breaking science and making cell therapy delivery routine and accessible.
Industries
Nr. of Employees
large (251-1000)
Patents
Compositions and methods for immune cell modulation in adoptive immunotherapies
US-12281329-B2
View DetailsCellular reprogramming using temporal and transient plasmid vector expression system
US-12247226-B2
View Details
Compositions and methods for immune cell modulation in adoptive immunotherapies
US-12281329-B2
View DetailsCellular reprogramming using temporal and transient plasmid vector expression system
US-12247226-B2
View DetailsProducts
iPSC Platform
A proprietary platform for creating genetically engineered, clonal master iPSC lines for developing off-the-shelf cellular therapies.
iPSC Platform
A proprietary platform for creating genetically engineered, clonal master iPSC lines for developing off-the-shelf cellular therapies.
iPSC Platform
A proprietary platform for creating genetically engineered, clonal master iPSC lines for developing off-the-shelf cellular therapies.
iPSC Platform
A proprietary platform for creating genetically engineered, clonal master iPSC lines used to develop off-the-shelf cellular immunotherapies.
FT819
An off-the-shelf, iPSC-derived CAR T-cell product candidate targeting CD19 for treating systemic lupus erythematosus and other autoimmune diseases.
FT819
An off-the-shelf, iPSC-derived CAR T-cell product candidate targeting CD19 for treating systemic lupus erythematosus and other autoimmune diseases.
iPSC Platform
A proprietary platform for creating genetically engineered, clonal master iPSC lines for developing off-the-shelf cellular therapies.
iPSC Platform
A proprietary platform for creating genetically engineered, clonal master iPSC lines for developing off-the-shelf cellular therapies.
iPSC Platform
A proprietary platform for creating genetically engineered, clonal master iPSC lines for developing off-the-shelf cellular therapies.
iPSC Platform
A proprietary platform for creating genetically engineered, clonal master iPSC lines used to develop off-the-shelf cellular immunotherapies.
FT819
An off-the-shelf, iPSC-derived CAR T-cell product candidate targeting CD19 for treating systemic lupus erythematosus and other autoimmune diseases.
FT819
An off-the-shelf, iPSC-derived CAR T-cell product candidate targeting CD19 for treating systemic lupus erythematosus and other autoimmune diseases.
News & Updates
On March 16, 2017, Fate Therapeutics announced its financial results for Q4 2016 and the full year.
On March 16, 2017, Fate Therapeutics hosted a conference call to discuss its Q4 2016 and full year earnings.
From June 14-17, 2017, Fate Therapeutics hosted a focus session at the ISSCR annual meeting in Boston, discussing off-the-shelf natural killer cell cancer immunotherapy.
On March 16, 2017, Fate Therapeutics announced its financial results for Q4 2016 and the full year.
On March 16, 2017, Fate Therapeutics hosted a conference call to discuss its Q4 2016 and full year earnings.
From June 14-17, 2017, Fate Therapeutics hosted a focus session at the ISSCR annual meeting in Boston, discussing off-the-shelf natural killer cell cancer immunotherapy.